FOXP1 and prostate cancer: To learn whether ELAC2 expression might be particularly linked to recurrent genomic deletions in prostate cancer, nuclear ELAC2 expression was compared to 10q23 (PTEN), 3p13 (FOXP1), 6q15 (MAP3K7) and 5q21 (CHD1) deletion.